Until 2011, the standard treatment for CHC was based on IFN-α, but in recent years, new direct-acting antivirals (DAAs), specifically targeting essential viral proteins have been introduced, in combination with IFN-based therapies and new, IFN-free regimes. Here, IFNA1 is linked to cryohydrocytosis.